studies

la/mBC - HER2 positive, ... vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS) (extension)detailed resultsALTTO (T plus L vs T), 2020 (REV) 1.16 [0.94; 1.43] 1.16[0.94; 1.43]ALTTO (T plus L vs T), 2020 (REV)10%4,190NAnot evaluable RFS/DFSdetailed resultsALTTO (T plus L vs T), 2020 (REV) 1.19 [0.99; 1.44] 1.19[0.99; 1.44]ALTTO (T plus L vs T), 2020 (REV)10%4,190NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-07-02 16:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 355,337,146,317 - treatments: 1303